Dextromethorphan-Bupropion Significantly Improves Major Depression Symptoms in Phase 2 ASCEND

Jennifer E. Engen

Investigative therapy dextromethorphan-bupropion (AXS-05) provided significantly improved major depression symptoms versus lone sustained-release bupropion while remaining tolerable in adult patients over 6 weeks, according to new phase 2 trial findings. In a randomized, double-blind, multi center, parallel-group study of the NMDA/sigma-1 receptor antagonist combination therapy, investigators observed significant improvements in […]